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Abstract
We present a case of 24-year-old asymptomatic pregnant woman in 18 hbd with hypertrophic cardiomyopathy (HCM). 
An echocardiogram revealed the hypertrophy of all walls of the left ventricle (LV), except for the posterolateral wall, from 
21 mm to 31 mm and septal hypertrophy up to 36 mm. During the first 48-h electrocardiogram (ECG) monitoring, five 
episodes of slow ventricular tachycardia (VT) consisted of three ExV up to 108/min were recorded. The 5-year HCM 
sudden cardiac death (SCD) risk score revealed the low risk of 2.25% — implantable cardioverter-defibrillator (ICD) not 
indicated. After a C-section delivery in 37 hbd, the control echocardiography revealed the enlargement of the LV wall 
hypertrophy up to 38 mm. In the 48-h ECG monitoring, two episodes of asymptomatic non-sustained VT consisted of 
four and seven ExV up to 162/min were registered. The 5-year HCM SCD risk came up to the intermediate level of 5.91% 
(ICD may be considered, class IIb B of recommendations). Based on the clinical and echocardiographic findings with 
dynamic progress in the LV hypertrophy, exacerbation of ventricular arrhythmias and increase of N-terminal natriuretic 
propeptide type B, the ICD was implanted. As presented by Maron & Maron at the European Society of Cardiology Con-
gress in London 2015, magnetic resonance scanning with the late gadolinium enhancement (LGE) estimation may be 
helpful in making the decision on the ICD implantation, especially within the group of intermediate 5-year risk of SCD 
(4–6%) with massive LV hypertrophy. The Authors suggest the extensive LGE (≥ 15%) as a primary SCD risk factor as well 
as a potential risk factor when conventional evaluation of the ICD implantation indications is ambiguous.
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Introduction
Hypertrophic cardiomyopathy (HCM) is a primary dise-
ase of myocardium that occurs in the increased left 
ventricular (LV) wall thickness with myocardial fibrosis. 
Most patients suffering from HCM have an elevated 
risk of sudden cardiac death (SCD). Thus, the precise 
evaluation of implantable cardioverter-defibrillator (ICD) 
implantation indications with estimation of the 5-year 
HCM SCD risk is necessary.
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from 21 mm to 31 mm and septal hypertrophy up to 36 mm 
were registered (Figure 1). During the first ECG monitoring, 
five episodes of slow ventricular tachycardia (VT) consisted 
of three ExV up to 108/min were recorded. The level of 
N-terminal natriuretic propeptide type B (NT-proBNP) was 
4606 pg/mL. The 5-year HCM SCD risk score revealed 
the low risk of 2.25% (ICD not indicated, class IIIB). The 
beta-blocker was administered.
In a third day after a C-section delivery in 37 hbd, 
the echocardiography revealed the enlargement of LV 
hypertrophy up to 38 mm. In the 48-h ECG monitoring, 
two episodes of asymptomatic non-sustained ventricular 
tachycardia (nsVT) consisted of four and seven ExV up to 
162/min were registered (Figure 2). An increase of the 
Case report
A 24-year-old asymptomatic pregnant woman in 18 hbd 
was admitted due to LV hypertrophy registered accidentally 
during the pregnancy ultrasonography (USG).
The patient presented with no abnormalities in physi-
cal examination, denied dyspnoea, chest pain, syncope, 
heart palpitations and the occurrence of HCM or SCD in 
relatives. In the resting electrocardiogram (ECG), non-spe-
cific anomalies of QRS-complex and ST-T were found. The 
echocardiogram revealed hypertrophic cardiomyopathy 
without left ventricular outflow tract obstruction (LVOTO) or 
mid-cavity obstruction also during the Valsalva manoeuvre. 
Except for the posterolateral wall, the hypertrophy of LV 
Figure 2. Non-sustained ventricular tachycardia in 48-h electrocardiogram monitoring
Figure 1A, B. Echocardiographic view
A B
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NT-proBNP to 7663 pg/mL was found. The 5-year HCM 
SCD risk came up to the intermediate level of 5.91% (ICD 
may be considered, class IIb B of recommendations). 
Based on the dynamic progress in the LV hypertrophy, the 
exacerbation of ventricular arrhythmias and the increase 
of NT-proBNP, the ICD was implanted.
Discussion
According to the European Society of Cardiology (ESC) 
guidelines, HCM (2014) [1] is a primary disease, that occurs 
in the increased left ventricular (LV) wall thickness with 
myocardial fibrosis. HCM by definition can be diagnosed 
when a left ventricle wall thickness ≥ 15 mm in at least 
one LV myocardial segments, measured by any imaging 
technique, while it cannot be explained by abnormal LV 
loading conditions. The decision of an ICD implantation 
as a primary prophylaxis of SCD is a very important part 
of treatment strategy in HCM. According to the newest 
ESC guidelines (2014), the main method of estimating the 
indications for ICD is the 5-year HCM risk-SCD. The risk of 
SCD should be assessed in every patient with HCM, when 
the disease is diagnosed and re-evaluated every 1–2 years 
or in case of changes in the clinical status (class I B of 
recommendations) [1].
As reported by Maron et al. [2], in the group of 239 HCM 
patients, massive LV hypertrophy was more often at the 
age of 18–39 than over 75 years (p = 0.03). In another 
research Maron et al. [3] report SCD in 44 cases from 
744 HCM patients, while in the subgroup with LV hypertro-
phy > 30 mm, SCD occurred in 50% (9/18) of the patients. 
In the research by Spirito et al. [4] on the group of 480 HCM 
patients, from 43 with LV hypertrophy > 30 mm, over 95% 
were asymptomatic or with poor symptoms and the risk 
of SCD was directly related to LV hypertrophy (p = 0.001). 
Elliot et al. [5] reported that from 630 HCM patients, SCD 
occurred in 39 cases and 10 of them had LV hypertrophy 
> 30 mm. The patients with LV hypertrophy over 30 mm 
had higher risk of the SCD (p = 0.049). Summarising, 
young patients with massive LV hypertrophy are especially 
endangered with SCD. Still, the presented patient is in the 
IIa class of recommendations for an ICD implantation [1].
In patients with the intermediate 5-year HCM SCD risk 
(4–6%), as presented by Maron & Maron at the ESC Con-
gress in London 2015 [6], magnetic resonance imaging 
(MRI) scanning with the late gadolinium enhancement 
(LGE) estimation may be helpful in making a decision on 
the ICD implantation. The LGE reflects the focal fibrosis of 
myocardium, increasing the risk of severe arrhythmias and 
SCD. Maron & Maron suggest the extensive LGE (≥ 15%) as 
a primary SCD risk factor as well as a potential risk factor 
when the conventional evaluation of the ICD implantation 
indications is ambiguous (Figure 3).
Described case highlights the role of the 5-year HCM 
SCD risk score and MRI scanning to guide treatment strate-
gy in HCM. The question is, if the subcutaneous ICD (S-ICD) 
might be a better option in this case according to 2015 ESC 
guidelines (class IIa C) [7]. In such cases, the main cause 
of the ICD implantation is the primary prevention of SCD 
without the potential need of heart pacing, while an S-ICD 
implantation is less invasive. Also the risk of endocarditis 
and thromboembolic complications is lower and the risk 
Figure 3. Risk stratification model for an implantable cardioverter-defibrillator (ICD) implantation as presented by Maron & Maron at the Eu-
ropean Society of Cardiology Congress, London 2015 [6]; VT — ventricular tachycardia; HCM — hypertrophic cardiomyopathy; SCD — sudden 
cardiac death; nsVT — non-sustained ventricular tachycardia; BP — blood pressure; LV — left ventricle; LGE — late-gadolinium enhancement; 
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of vessels fibrosis caused by ICD electrodes is minimali-
sed, what simplifies the potential heart transplantation. 
Finally, better cosmetic effect may be important especially 
for young women.
Conclusions
According to the ESC guidelines, evaluation of the 5-year 
SCD risk in HCM is one of the basic tools in qualification to 
ICD implantation. Estimation of the LGE in MRI scanning 
may be helpful in making a decision on the ICD implan-
tation in HCM patients, especially within the group of the 
intermediate 5-year risk of SCD (4–6%) with massive LV 
hypertrophy.
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Streszczenie
Zaprezentowano opis przypadku 24-letniej kobiety z kardiomiopatią przerostową bez objawów w 18. tygodniu ciąży. 
W echokardiografii przezklatkowej (TTE) uwidoczniono przerost wszystkich ścian lewej komory (LV) poza tylno-boczną, 
od 21 mm do 31 mm, oraz przerost przegrody międzykomorowej do 36 mm. W 48-godzinnym badaniu elektrokardiogra-
ficznym (EKG) metodą Holtera stwierdzono 5 epizodów częstoskurczu komorowego złożonych z 3 pobudzeń o częstości 
do 108/min. Wyliczono 5-letnie ryzyko nagłego zgonu sercowego (SCD) jako niskie — na poziomie 2,25% (wszczepialny 
kardiowerter-defibrylator [ICD] nie jest zalecany). Po porodzie drogą cięcia cesarskiego w 37. tygodniu ciąży w TTE 
uwidoczniono progresję przerostu mięśnia LV do 38 mm. W 48-godzinnym badaniu EKG metodą Holtera stwierdzono 
2 epizody bezobjawowego nieutrwalonego częstoskurczu komorowego z 4 oraz 7 pubudzeń o częstości do 162/min. 
Wyliczone 5-letnie ryzyko SCD zwiększyło się do 5,91% (klasa zaleceń IIb B dla ICD). Ze względu na całość obrazu 
klinicznego i echokardiograficznego, progresję przerostu ścian LV, nasilenie arytmii komorowej i zwiększenie stężenia 
N-końcowego propeptydu natriuretycznego typu B pacjentce wszczepiono ICD. U pacjentów z pośrednim 5-letnim ry-
zykiem SCD w kardiomiopatii przerostowej (4–6%), zgodnie z doniesieniem Maron i Maron z kongresu Europejskiego 
Towarzystwa Kardiologicznego (Londyn, 2015), ocena późnego wzmocnienia kontrastowego (LGE) w badaniu rezonansu 
magnetycznego może być pomocna w podjęciu decyzji o implantacji ICD. Autorzy wskazują na LGE większe lub równe 
15% jako czynnik ryzyka SCD kwalifikujący do implantacji ICD, a także czynnik rozstrzygający w przypadku niejedno-
znacznych wskazań do wszczepienia ICD.
Słowa kluczowe: kardiomiopatia przerostowa, wytyczne ESC, wszczepialny kardiowerter-defibrylator, podskórny  
kardiowerter-defibrylator
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